Company / PP&E (Net)
INOVIO PHARMACEUTICALS, INC. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$2.5M
FY2025
5-year range
$2.5M / $17.5M
FY2021-FY2025
Trend
-30.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has declined for 4 consecutive years, from $17M in FY2021 to $3M in FY2025.
Based on SEC 10-K filings.
$3M in FY2025 with a 5-year CAGR of -25.9%.
Declined from $5M to $3M over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -31.1%
- 5-Year CAGR
- -25.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- INOVIO PHARMACEUTICALS, INC.'s pp&e (net) has declined for 4 consecutive years.
- 5-year CAGR of -25.9%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 30.9% year-over-year.
- Peak pp&e (net) was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.5M | -30.9% |
| FY2024 | $3.7M | -26.2% |
| FY2023 | $5.0M | -35.8% |
| FY2022 | $7.7M | -55.7% |
| FY2021 | $17.5M | +53.8% |
| FY2020 | $11.3M | -11.2% |
| FY2019 | $12.8M | -19.9% |
| FY2018 | $15.9M | -12.9% |
| FY2017 | $18.3M | +103.0% |
| FY2016 | $9.0M | +23.5% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026